The use of ureteral stenting for tumor surrounded abdominal ureter in gynecologic oncology

Year 2020, Volume: 2 Issue: 2, 76 - 79, 29.06.2020

İlker Selcuk , Burak Ersak , Atahan Toyran , Yalçın Kızılkan , Hakan Raşit Yalçın , Bülent Özdal

Abstract

For ovarian cancer, recurrence is commonly noted, and the tumor implants involve the bowels, ureter, liver, spleen, parietal peritoneum, diaphragm or the mesenteric peritoneum in recurrent cases. In tumor disseminated cases, the dissection of the ureter will be difficult, and an injury can easily be performed. Ureteral stenting is a feasible option for advanced oncologic cases to facilitate ureteral dissection and avoid probable injuries. Here, we demonstrate ureteral stenting for the left abdominal ureter in a recurrent ovarian cancer patient to resect a lateral aortic tumor mass.

Keywords

ureteral stenting, ovarian cancer, anatomy, cytoreduction, injury

Jinekolojik onkolojide tümör sarılı abdominal üreter için üreteral stent kullanımı

Abstract

Over kanserinde rekürens sıklıkla gözlenir ve rekürrent vakalarda barsaklar, üreter, karaciğer, dalak, parietal periton, diafragma veya mezenterik periton tümör implantları ile tutulabilir. Yaygın tümör olan vakalarda ureter diseksiyonu zor olabilir ve zedelenme rahatlıkla oluşabilir. Üreteral stent kullanımı, ileri onkolojik vakalarda uygulanabilecek bir seçenek olup, üreteral diseksiyonu kolaylaştırır ve olası zedelenmeleri azaltır. Burada, lateral aortik tümöral kitlesi olan rekürrent over kanseri hastasında sol abdominal üreter için üreteral stent kullanımı sunulmuştur.

Keywords

ureteral stent, over kanseri, anatomi, sitoredüksiyon, zedelenme

References

• Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011; 21:289-295.
• Hancerliogulları O, Selcuk I, Ersak B, et al. Surgical Outcomes of Epithelial Ovarian Cancer Patients Who Underwent Intestinal Resection During Primary and Secondary Cytoreductive Surgery. Jinekoloji - Obstetrik ve Neonatoloji Tıp Dergisi 2018; 15:150-154.
• Ang C, Naik R. The value of ureteric stents in debulking surgery for disseminated ovarian cancer. Int J Gynecol Cancer 2009; 19:978-980.
• Gilmour DT, Das S, Flowerdew G. Rates of urinary tract injury from gynecologic surgery and the role of intraoperative cystoscopy. Obstet Gynecol 2006; 107:1366-1372.
• Fugazzola P, Coccolini F, Tomasoni M, et al. Routine prophylactic ureteral stenting before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Safety and usefulness from a single-center experience. Turk J Urol 2019; 45:372-376.
• Abu-Zaid A, Abou Al-Shaar H, Azzam A, et al. Routine ureteric stenting before cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in managing peritoneal carcinomatosis from gynecologic malignancies: a single-center experience. Ir J Med Sci 2017; 186:269-273.
• Chou MT, Wang CJ, Lien RC. Prophylactic ureteral catheterization in gynecologic surgery: a 12-year randomized trial in a community hospital. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:689-693.
• Kuno K, Menzin A, Kauder HH, Sison C, Gal D. Prophylactic ureteral catheterization in gynecologic surgery. Urology 1998; 52:1004-1008.
• Coccolini F, Ansaloni L, Concetti S, Schiavina R, Martorana G. The importance of ureteral stenting in major debulking surgery. Int J Gynecol Cancer 2010; 20:479.
• Lange D, Bidnur S, Hoag N, Chew BH. Ureteral stent-associated complications--where we are and where we are going. Nat Rev Urol 2015; 12:17-25.